ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 192,57
0,00%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sagiment Biosciences Inc (SGMT)

  7. Sagiment Biosciences Inc (SGMT) Actualités

SGMT

Sagiment Biosciences (SGMT)

Sagiment Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SGMT
DateHeureSourceTitreSymboleSociété
13/06/202412h07Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SGMTSagiment Biosciences Inc
07/06/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMTSagiment Biosciences Inc
06/06/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMTSagiment Biosciences Inc
15/05/202413h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGMTSagiment Biosciences Inc
08/05/202422h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SGMTSagiment Biosciences Inc
25/03/202412h00GlobeNewswire Inc.Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsNASDAQ:SGMTSagiment Biosciences Inc
25/03/202411h15GlobeNewswire Inc.Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SGMTSagiment Biosciences Inc
29/02/202414h00GlobeNewswire Inc.Sagimet Biosciences to Participate in Two Upcoming Investor ConferencesNASDAQ:SGMTSagiment Biosciences Inc
15/02/202400h10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SGMTSagiment Biosciences Inc
26/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGMTSagiment Biosciences Inc
26/01/202402h58GlobeNewswire Inc.Sagimet Biosciences Announces Pricing of Public Offering of Series A Common StockNASDAQ:SGMTSagiment Biosciences Inc
24/01/202412h08Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SGMTSagiment Biosciences Inc
23/01/202423h45GlobeNewswire Inc.Sagimet Biosciences Announces Proposed Public Offering of Series A Common StockNASDAQ:SGMTSagiment Biosciences Inc
23/01/202423h31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SGMTSagiment Biosciences Inc
22/01/202413h00GlobeNewswire Inc.Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHNASDAQ:SGMTSagiment Biosciences Inc
04/12/202314h00GlobeNewswire Inc.Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst ClinicNASDAQ:SGMTSagiment Biosciences Inc
28/11/202314h00GlobeNewswire Inc.Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development SummitNASDAQ:SGMTSagiment Biosciences Inc
22/11/202314h00GlobeNewswire Inc.Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:SGMTSagiment Biosciences Inc
13/11/202314h00GlobeNewswire Inc.Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SGMTSagiment Biosciences Inc
10/11/202314h30GlobeNewswire Inc.Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023NASDAQ:SGMTSagiment Biosciences Inc
24/10/202317h00GlobeNewswire Inc.Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023NASDAQ:SGMTSagiment Biosciences Inc
18/10/202322h05GlobeNewswire Inc.Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceNASDAQ:SGMTSagiment Biosciences Inc
27/09/202322h05GlobeNewswire Inc.Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent GlioblastomaNASDAQ:SGMTSagiment Biosciences Inc
21/08/202322h02GlobeNewswire Inc.Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SGMTSagiment Biosciences Inc
15/08/202322h04GlobeNewswire Inc.Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public OfferingNASDAQ:SGMTSagiment Biosciences Inc
20/07/202322h05GlobeNewswire Inc.Sagimet Biosciences Announces Leadership ChangesNASDAQ:SGMTSagiment Biosciences Inc
14/07/202303h10GlobeNewswire Inc.Sagimet Biosciences Announces Pricing of Upsized Initial Public OfferingNASDAQ:SGMTSagiment Biosciences Inc
23/06/202308h30GlobeNewswire Inc.Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023NASDAQ:SGMTSagiment Biosciences Inc
07/06/202315h00GlobeNewswire Inc.Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023NASDAQ:SGMTSagiment Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SGMT

Dernières Valeurs Consultées

NASDAQ
NCAXX
Nations California Tax Exempt Re
BIT
P1L0G5
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés